8281 related articles for article (PubMed ID: 24961100)
1. [Antitumor efficacy of the recombinant Newcastle disease virus rNDV-IL15 on melanoma models].
Niu ZS; Bai FL; Sun T; Tian H; Yin JC; Cao HW; Yu D; Tian GY; Wu YZ; Li DS; Ren GP
Yao Xue Xue Bao; 2014 Mar; 49(3):310-5. PubMed ID: 24961100
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
[TBL] [Abstract][Full Text] [Related]
3. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.
Xu X; Sun Q; Mei Y; Liu Y; Zhao L
Cancer Sci; 2018 Feb; 109(2):279-288. PubMed ID: 29224228
[TBL] [Abstract][Full Text] [Related]
4. [Antitumoral efficacy by systemic delivery of cationic liposome-plasmid interleukin-15 complexes in murine models of lung metastasis].
Teng X; Zhou XK; Zhang YB; Qiu J; Mao YQ; Deng HX; Li J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Feb; 28(2):148-52. PubMed ID: 22304773
[TBL] [Abstract][Full Text] [Related]
5. TNF-related Apoptosis-inducing Ligand Delivered by rNDV is a Novel Agent for Cancer Gene Therapy.
Bai FL; Tian H; Yu YH; Yin JC; Ren GP; Zhou B; Li DS
Technol Cancer Res Treat; 2015 Dec; 14(6):737-46. PubMed ID: 24988059
[TBL] [Abstract][Full Text] [Related]
6. Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect.
Pan Z; He J; Rasoul LM; Liu Y; Che R; Ding Y; Guo X; Yang J; Zou D; Zhang H; Li D; Cao H
PLoS One; 2016; 11(10):e0164723. PubMed ID: 27736965
[TBL] [Abstract][Full Text] [Related]
7. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
8. [Rescue of a recombinant Newcastle disease virus expressing the green fluorescent protein].
Ge JY; Wen ZY; Wang Y; Bao ED; Bu ZG
Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):547-51. PubMed ID: 17037052
[TBL] [Abstract][Full Text] [Related]
9. IL15 combined with Caspy2 provides enhanced therapeutic efficiency against murine malignant neoplasm growth and metastasis.
Yang Y; Zhang XM; Zhang N; Cheng L; Li C; Zhang S; Zhang JF; Dai L; Tian HW; Yan N; Fan P; Dai LX; Xu F; Shi G; Chen XL; Du T; Li YM; Wei YQ; Deng HX
Cancer Gene Ther; 2012 Jul; 19(7):460-7. PubMed ID: 22539063
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.
An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G
J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice.
Song Y; Liu Y; Hu R; Su M; Rood D; Lai L
Mol Cancer Ther; 2016 Oct; 15(10):2413-2421. PubMed ID: 27474151
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
13. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.
Xu X; Sun Q; Yu X; Zhao L
Virus Res; 2017 Apr; 233():35-41. PubMed ID: 28286036
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor response to fibrosarcoma by Newcastle disease virus-infected tumor vaccine.
Takamura-Ishii M; Miura T; Nakaya T; Hagiwara K
Med Oncol; 2017 Sep; 34(10):171. PubMed ID: 28864944
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma.
Yi C; Huang Y; Guo ZY; Wang SR
Acta Pharmacol Sin; 2005 May; 26(5):629-34. PubMed ID: 15842785
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
20. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
